In this episode recorded live at LongevityFest 2025, hosts Lauri Hoffman and Dr. Lexi Gonzales interview Dr. Myles Spar, Executive Medical Director at Wonder Health, and Dr. Edward Walker, lead scientist behind Amarasate, the hops extract at the core of Calocurb The conversation explores how triple satiety hormone activation may offer practitioners a more nuanced approach to metabolic and weight care—both as an alternative to GLP-1 injectables and as a supportive tool before, during, and after pharmaceutical intervention. The guests focus especially on one of the most urgent concerns in today’s weight-loss landscape: how to support meaningful fat loss without sacrificing lean muscle mass, metabolic resilience, or long-term continuity of care.

Key Discussion Points

• The Muscle Preservation Problem: Dr. Spar explains that in clinical practice, patients on GLP-1s are often losing lean muscle mass alongside fat mass, which raises significant concerns for longevity. He notes that muscle mass—and even measures like thigh circumference and grip strength—may be more predictive of long-term health than fat loss alone.

• Why Body Composition Matters More Than the Scale: The discussion reframes weight loss away from pounds alone and toward functional assessment. DEXA scans, waist circumference, and targeted muscle measurements can help practitioners monitor whether patients are actually preserving the tissue that matters most.

• Triple Satiety Hormone Activation: Dr. Walker explains that CaloCurb works by stimulating endogenous satiety signaling at the gut wall, including GLP-1, CCK, and PYY. Unlike injectable therapies that provide an exogenous signal, this approach is designed to prompt the body’s own hormone release.

• Why One 250 mg Capsule Is Different From Two Smaller Capsules: A major clinical distinction of CaloCurb Clinical is not just the total dose, but the delivery format. Dr. Walker explains that one 250 mg capsule creates a higher concentration at the intestinal surface, which appears to produce a stronger hormone response than splitting the same amount across two smaller capsules.

• Supporting Continuity Through GLP-1 Use and De-escalation: The guests discuss how CaloCurb may help practitioners maintain endogenous satiety signaling while using the lowest effective GLP-1 dose possible. This may become especially relevant during tapering, when rebound hunger and weight regain are common concerns.

Actionable Insights for Practitioners

• Assess More Than Weight: Whenever possible, use DEXA scans to track body composition. If that is not feasible, monitor waist circumference along with thigh, biceps, and chest measurements to help detect unintended muscle loss.

• Start With Lifestyle and Endogenous Support First: Dr. Spar describes beginning with foundational lifestyle work—diet, sleep, and time-restricted eating—along with CaloCurb before escalating to a GLP-1. He often gives this approach three months before adding pharmaceutical support.

• Use the Lowest Effective Pharmaceutical Dose: If a GLP-1 is added, Dr. Spar continues CaloCurb in the protocol in order to reduce reliance on higher injectable dosing and maintain a clearer clinical target tied to body composition, blood sugar, and waist circumference.

• Ramp Up to Tolerance: Both guests emphasize starting at the lower 125 mg dose and increasing gradually to 250 mg twice daily when appropriate. This stepwise approach helps minimize gastrointestinal discomfort and improves adherence.

• Customize for Patient Patterns: Dr. Spar notes that some patients—particularly “night eaters” or those working on time-restricted eating—may need more tailored evening support to help manage late-night cravings and improve compliance.

Featured Resources & Calls to Action

• Calocurb: a natural appetite control formula designed to support weight health and metabolic outcomes through the activation of the body's own satiety hormones

• Calocurb Clinical: A new practitioner-exclusive formulation featuring a 250mg dose designed for higher efficacy under clinical supervision.

• Resource: Visit the Innovations in Clinical Implementation landing page for exclusive resources.

Analogies for Understanding

• The Counteractive Force: Dr. Walker offers a useful contrast between endogenous and exogenous approaches: while injected GLP-1s may signal to the body that it does not need to produce as much of its own hormone, CaloCurb acts as a counteractive force—encouraging the body to continue making its own GLP-1 and related satiety hormones. This helps frame the product not simply as an appetite aid, but as a potential bridge for preserving continuity across different phases of metabolic care.